Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA new page revision tag, v3.5.3, was added and the previous revision tag, v3.5.2, was removed. This reflects a metadata update to the page rather than a change to study content or results.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision: v3.5.2 is now shown in the page footer, replacing Revision: v3.5.0. No changes to study content or data are indicated.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded the disease term 'Squamous cell carcinoma of the head and neck' and a Resources entry for Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed. This appears to be a technical site update with no changes to trial content.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check91 days agoChange DetectedAdded Revision: v3.4.2. Deleted the government funding lapse notice and related operating-status information (Revision: v3.4.1).SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.